
New York Times Opinion
“People with obesity or drug addictions are often seen as selfish, shamefully lacking in willpower and lazy,” writes Maia Szalavitz in an essay for @nytopinion. “Both are derided for apparently abandoning themselves to indulgence, even though research shows that they are more likely to be trying to ease emotional pain.” Ozempic is one of a new class of diabetes and obesity drugs called GLP-1 receptor agonists that work differently from other medications. “Unlike stimulants, which can be addictive, these drugs may fight addictions, and not just those related to food,” explains Maia. One of the greatest things about these drugs is the reduction of stigma, she adds. “It is long past time to stop shaming people with disorders of appetite in a futile attempt to tame our own fears of loss of control. Whatever condition is being treated, we all deserve the easiest possible path to recovery.” #ozempic #weightloss #diabetes #addiction #nytopinion